Understanding economic evidence for the prevention and treatment of atopic eczema.
CONCLUSIONS: The current level of economic evidence for interventions aimed at preventing and treating eczema is limited compared to that available for clinical outcomes suggesting that greater collaboration between clinicians and economists might be beneficial. This article is protected by copyright. All rights reserved.
PMID: 30693473 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - January 28, 2019 Category: Dermatology Authors: Sach TH, McManus E, Levell NJ Tags: Br J Dermatol Source Type: research
Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial
ConclusionPimecrolimus showed earlier clinical response and less recurrence rate compared with standard topical corticosteroid in symptomatic OLP lesions, and both treatment reduced CD133-positive CSC population.Clinical relevanceThe study proved the benefits of topical pimecrolimus in early management of painful lesions of OLP and its ability to inhibit CSCs, suggesting a possible role in reducing risk of malignant transformation. (Source: Clinical Oral Investigations)
Source: Clinical Oral Investigations - January 26, 2019 Category: Dentistry Source Type: research
A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor
To the Editor: Topical corticosteroids are among the cornerstone treatments of atopic dermatitis (AD); however, prolonged use is associated with skin atrophy, hypopigmentation, and telangiectasia.1 Nonsteroidal alternatives include topical calcineurin inhibitors such as pimecrolimus and tacrolimus and the phosphodiesterase 4 inhibitor crisaborole, which have application site pain as a side effect. The mechanism by which crisaborole induces pain is unknown. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - November 1, 2018 Category: Dermatology Authors: Christine Pao-Ling Lin, Samantha Gordon, Min Ji Her, David Rosmarin Tags: Research letter Source Type: research
Allergic contact dermatitis caused by mupirocin and pimecrolimus
Contact Dermatitis, EarlyView. (Source: Contact Dermatitis)
Source: Contact Dermatitis - October 12, 2018 Category: Dermatology Authors: Amy J. Zhang,
Erin M. Warshaw Source Type: research
A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas.
Conclusions These recommendations are expected to optimize AD management in patients across the Middle East.
PMID: 30222017 [PubMed - as supplied by publisher] (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - September 18, 2018 Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Safety of Topical Calcineurin Inhibitors for Hailey-Hailey Disease
To the Editor Dr Haley and colleagues described a patient with Hailey-Hailey disease (HHD) in a JAMA Clinical Challenge article. The authors stated that long-term topical calcineurin inhibitors (TCIs) such as tacrolimus or pimecrolimus could be applied to control HHD because they lacked the adverse effects of topical corticosteroids. However, the US Food and Drug Administration (FDA) issued a public health advisory in 2005 about a potential cancer risk associated with the use of tacrolimus, based on animal studies and case reports in a small number of patients. Although the finding is controversial, the number of patients ...
Source: JAMA - September 18, 2018 Category: General Medicine Source Type: research
Translational research with topical calcineurin inhibitors in early MF
Introduction and aims: Activation of calcineurin signaling pathway is found in about 50% of human MF cases. Our phase II, multicentric, single arm, clinical trial with topical calcineurin inhibitors (TCIs) in early MF patients demonstrated an overall response rate of 56.4% to pimecrolimus 10 mg/g cream. (Source: European Journal of Cancer)
Source: European Journal of Cancer - August 29, 2018 Category: Cancer & Oncology Authors: Lidia Maro ñas-Jiménez, Teresa Estrach, Cristina Muniesa, Ricardo Fernández de Misa, Onofre San martín, Fernando Gallardo, Blanca Jiménez, May Sanchez-Beato, Laura Cereceda, J.P. Vaqué, M.A. Piris, Pablo Ortiz-Romero Source Type: research
Epidermal Growth Factor Relieves Inflammatory Signals in Staphylococcus aureus-Treated Human Epidermal Keratinocytes and Atopic Dermatitis-Like Skin Lesions in Nc/Nga Mice.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a defective immunologic barrier, which is aggravated by Staphylococcus aureus (S. aureus). Epidermal growth factor (EGF) suppresses inflammation and EGF receptor inhibitors increased S. aureus colonization. Thus, we investigated the potential roles of EGF in AD, which is often aggravated by S. aureus. We determined how EGF affects the expression of inflammatory cytokines and antimicrobial peptides (AMPs) in human epidermal keratinocytes (HEKs) treated with heat-inactivated S. aureus (HKSA) in vitro and 2,4-dinitrochlorobenzene-indu...
Source: Biomed Res - June 6, 2018 Category: Research Authors: Choi SY, Lee YJ, Kim JM, Kang HJ, Cho SH, Chang SE Tags: Biomed Res Int Source Type: research
[Annular lichenoid dermatitis of youth: A case report and literature review].
CONCLUSION: Annular lichenoid dermatitis of youth (ALDY) is a poorly known distinctive entity within the lichenoid dermatitis family. Clinical-histological correlation is essential to diagnosis. The etiology is still unknown and the course is mostly chronic.
PMID: 29673747 [PubMed - as supplied by publisher] (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - April 16, 2018 Category: Dermatology Authors: Debois D, Dargent JL, Ngendahayo P, Roquet-Gravy PP Tags: Ann Dermatol Venereol Source Type: research
[Chronic prurigo].
Authors: Pereira MP, Nau T, Zeidler C, Ständer S
Abstract
Chronic prurigo is a disease characterized by the presence of chronic pruritus and singular or multiple usually hyperkeratotic symmetrically distributed itchy papules, nodules, and/or plaques. This condition is difficult to treat and leads to a substantial impairment of the quality of life. It may originate from dermatological, systemic, neurological, psychiatric/psychosomatic, multifactorial or unknown conditions causing itch, which lead to prolonged scratching behavior and sensitization mechanisms and ultimately to the development of pruriginou...
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - March 28, 2018 Category: Dermatology Tags: Hautarzt Source Type: research
Genital hypertrophicus lichen planus successfully treated with topical pimecrolimus.
Authors: DE Paola M, DE Piano E, Pisani C, Mallarini M, Bilenchi R
PMID: 29564883 [PubMed - in process] (Source: Giornale Italiano di Dermatologia e Venereologia)
Source: Giornale Italiano di Dermatologia e Venereologia - March 25, 2018 Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research
A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation & ndash; JOELLE study)
(Source: Clinical Epidemiology)
Source: Clinical Epidemiology - March 13, 2018 Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
Topical pimecrolimus for paediatric cutaneous mastocytosis
ConclusionsTopical therapy with pimecrolimus 1% cream should be considered in the treatment of CM. (Source: Clinical And Experimental Dermatology)
Source: Clinical And Experimental Dermatology - February 20, 2018 Category: Dermatology Authors: J. Mashiah, A. Harel, C. Bodemer, S. Hadj ‐Rabia, I. Goldberg, E. Sprecher, A. Kutz Tags: Original article Source Type: research
Topical pimecrolimus for paediatric cutaneous mastocytosis
Clinical and Experimental Dermatology, EarlyView. (Source: Clinical And Experimental Dermatology)
Source: Clinical And Experimental Dermatology - February 20, 2018 Category: Dermatology Authors: J. Mashiah
,
A. Harel
,
C. Bodemer
,
S. Hadj ‐Rabia
,
I. Goldberg
,
E. Sprecher
,
A. Kutz Source Type: research
